Camptothecin analogues/cisplatin: An effective treatment of advanced bladder cancer in a preclinical in vivo model system

Journal of Urology

Volumn 160, Issue 1, 1998, Pages 252-256

  Keane, Thomas E ^a   El Galley, Rizk E S ^a   Sun, Carrie ^a   Petros, John A ^a   Dillahey, Dirk ^a   Gomaa, A ^a   Graham Jr , Sam D ^a   Mcguire III, William P ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Camptothecin analogues; Cisplatin

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN; CISPLATIN; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0032324186     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63099-4     Document Type: Article

References (21)

1. Loehrer, P. J. Sr, Einhorn, L. H., Elson, P. J., Crawford, E. D. Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F. and Lowe, G. A.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial tumors. J. Clin. Oncol., 10: 1066,1992.
2. Walther, P. J.: Combined treatment approaches in regionally advanced bladder cancer. Urol. Clin. North Am., 19: 761,1992.
3. DeVita, V. T., Jr.: Principles of chemotherapy. In: Cancer-Principles and Practice of Oncology. Edited by V. T. DeVita, Jr., S. Hellman, and S. Rosenberg. Philadelphia: J. B. Lippincott Co., pp 268, 1985.
4. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., MCPhail, A. T. and Sim, G. A.: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888,1966.
5. Horwitz, S. B., Chang, C. S. C. K. and Grollman, A. P.: Studies on camptothecin. 1. Effects on nucleic acid and protein synthesis. Mol. Pharmacol, 7: 632, 1971.
6. Hsiang, Y. H. and Liu, L. F.: Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug Camptothecin. Cancer Res., 48: 1722, 1988.
7. Kunimoto, T., Nitta, K., Tanaka, T. Uchara, N., Baga, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M.: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, against murine tumors. Cancer Res., 47: 5944, 1987.
8. Fukuoka, M. Niitani, H. Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyami, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T.: A phase 11 study of CPT-11, a new derivative of camptothecin, for previously untreated non small cell lung cancer. J. Clin. Oncol., 10: 16, 1992.
9. Negoro S. Fukuoka M. Niitani H. and Taguchi, T.: Phase 11 study of CPT-11, a new camptothecin derivative, in small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 10: 241, 1991.
10. Keane, T. E., Rosner, G., Donaldson, J. T., Norwood, D. L., Poulton, S. H. and Walther, P. J.: Dipyridamole-cisplatin potentiation enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J. Urol., 144: 1004, 1990.
11. Bogden. A. E., Kelton, D. E., Cobb, W. R. and Esber, H. J.: A rapid screening method for testing chemotherapeutic agents on human tumor xenografts. In: Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research. Edited by D. P. Houchens and A. A. Ovejera. New York: Gustav Fisher, pp. 231-250, 1978.
12. Bogden, A. E., Griffin, W., Reich, S. D., Costanza, M. E., and Cobb, W. R.: Predictive testing with the subrenal capsule assay. Cancer Treat. Rev., 11(A): 113, 1984.
13. Keane, T. E., Rosner, G., Gingrich, J. R., Poulton, S. H. and Walther, P. J.: The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. J. Urol., 146: 1418, 1991.
14. Keane, T. E., Gingrich, J. R., Rosner, G., Webb, K. S., Poulton, S. H. and Walther, P. J.: Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res., 54: 475, 1994.
15. Rosner, B.: Fundamentals of Biostatistics. 2nd ed. Boston: Duxbury Press, pp 467-472.
16. Rosner, B.: Fundamentals of Biostatistics. 2nd Ed. Boston: Duxbury Press, pp 288-293.
17. Sternberg, C. N., Yagoda, A., Scher, H. I. Watson, R., Hess, H., Morse, M., Sogani, P., Vaughan, E. D., Bawder, N., Weiselberg, L., Geller, N., Hollander, P., Lipperman, R., Fair, W. and Whitmore, W.: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 139: 461, 1988.
18. Del-Bino, G. D., Lassota, P. and Darsynkiewicz, Z.: The S-phase cytotoxicity of camptothecin. Exp. Cell Res., 193: 27, 1991.
19. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A. and Houghton, J. D.: Therapeutic efficacy of the topoisomerase1 inhibitor 7-ethyl-10(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase1 inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823, 1993.
20. Hsiang, Y. H., Hertzberg, R., Hecht, S. and Lui, L.: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1. J. Biol. Chem., 260: 14873, 1985.
21. Lippard, S. J.: Overview. In: Platinum Coordination Complexes in Cancer Chemotherapy. Edited by M. P. Hacker, E. P. Douple and I. H. Krakoff. Boston: Martinus Nijhoff Publishing, pp. 11-13, 1984.